Journal
BLOOD
Volume 121, Issue 12, Pages 2199-2212Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-10-408021
Keywords
-
Categories
Ask authors/readers for more resources
Recent molecular studies of fetal hemoglobin (HbF) regulation have reinvigorated the field and shown promise for the development of clinical HbF inducers to be used in patients with beta-thalassemia and sickle cell disease. However, while numerous promising inducers of HbF have been studied in the past in beta-thalassemia patient populations, with limited success in some cases, no universally effective agents have been found. Here we examine the clinical studies of such inducers in an attempt to systematically review the field. We examine trials of agents, including 5-azacytidine, hydroxyurea, and short-chain fatty acids. This review highlights the heterogeneity of clinical studies done on these agents, including both the patient populations examined and the study end points. By examining the published studies of these agents, we hope to provide a resource that will be valuable for the design of future studies of HbF inducers in beta-thalassemia patient populations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available